<DOC>
	<DOC>NCT01906190</DOC>
	<brief_summary>This clinical study will be performed in subjects aged 12-60 years old enrolled in NCT01310374 who received 2010 seasonal influenza vaccine to evaluate the persistence of the immune response of influenza vaccine up to 24 months after vaccination.</brief_summary>
	<brief_title>Persistence of Immune Response After Vaccination With Influenza Vaccine</brief_title>
	<detailed_description>Subjects were previously vaccinated at 12 to 60 years of age with 2010 seasonal influenza vaccine.The persistence phase starts 24 months after the primary vaccination and blood samples will be taken at 6, 12, 18 and 24 months after primary vaccination. Subjects whose antibody titer less than 1:40 at 6 months after primary vaccination will receive a booster dose of influenza vaccine.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>aged 1260 years old male or nonpregnant female volunteers received 2010 seasonal influenza vaccine clinically healthy as determined by: medical history inquiring and physical examination provide written informed consents before joining the trial without history of 2010 seasonal influenza vaccine administration, allergic to any ingredient of vaccine, autoimmune disease or immunodeficiency, severe adverse reaction after vaccination, such as allergies, hives, breathing difficulties, angioedema or abdominal pain, severe acute and chronic diseases axillary temperature over 37.0â„ƒ at the time of vaccination.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>immune response</keyword>
	<keyword>persistence</keyword>
</DOC>